VGX Pharmaceuticals, Inc., a leading developer of novel drugs and vaccines, announced today that it has signed a collaboration and license agreement with VGX International, Inc. The Agreement provides the technical support and manufacturing process technology necessary for VGX International to construct and operate a large-scale cGMP, DNA plasmid manufacturing facility in Korea – its… Read More »
VGX Pharmaceuticals announces an agreement with VGX International to build a large scale cGMP DNA manufacturing plant in Korea
VGX Pharmaceuticals adds cGMP plasmid DNA manufacturing capacity
VGX Pharmaceuticals, Inc., a leading manufacturer of cGMP-grade DNA plasmids, announced today that it has expanded its manufacturing capacity with the installation and testing of a new 500-liter scale fermentor in its cGMP manufacturing facility in The Woodlands, Texas. The new fermentor gives VGX significantly more flexibility than its current 100-liter production scale. In addition… Read More »
VGX Pharmaceuticals Announces Issuance of Two Key U.S. Patents Covering DNA Plasmid Manufacturing Technology and the Treatment of Anemia
VGX Pharmaceuticals today announced that it has been granted U.S. Patent number 7,238,522 covering its DNA plasmid manufacturing technology. The patent entitled, “Device and Methods for Biomaterial Production” represents the first to issue of a series of applications related to VGX’s novel approach to DNA plasmid manufacturing. “We are very pleased to have been granted… Read More »